Sample Size Determination. The Fundamentals of Biostatistics in Clinical Research Workshop India, March 2007 Mario Chen

Size: px
Start display at page:

Download "Sample Size Determination. The Fundamentals of Biostatistics in Clinical Research Workshop India, March 2007 Mario Chen"

Transcription

1 Sample Size Determination The Fundamentals of Biostatistics in Clinical Research Workshop India, March 2007 Mario Chen

2 Framework Objectives Type of Inference: Estimation or Hypothesis Testing Study Design: Type of Study and Sample Size Data Collection Data Management Data Analysis

3 Selection of summary measure Objective Population Endpoint Individual Summary measure* Sample Parameter Population * Depends of primary analysis method

4 Sample Size for Estimation Necessary Components: 1. Indicator or summary measure of interest (proportions or means) 2. Desired Confidence Level (1-α) 3. Desired Precision Level (d) 4. Expected Variability in the study population: For means (σ) For proportions (P)

5 Sample Size for Estimation (Proportions) Example: 1. Summary measure: Prevalence of Vibrio Cholerae 2. Confidence Level: 95% 3. Precision Level: d = 3 percent points, i.e n = Variability: Estimate of P = 15% (from previous studies) Recommendation: If If there is is not a good estimate for P, use P closest to to 50% to to be conservative

6 Sample Size for Estimation (Means) Example: 1. Summary measure: Mean hydrocele size among filariasis infected patients 2. Confidence Level: 95% 3. Precision Level: d = 1.5 mm. 4. Variability: Estimate for σ = 5.7 mm. n = 58 To estimate σ we can use previous studies, expert advice, or or a pilot study

7 Sample Size for Hypothesis Testing Necessary Components: 1. Summary measure of interest (proportions or means) 2. Statistical Hypotheses 3. Significance Level (α) 4. Desired Power (1-β)

8 Sample Size for Hypothesis Testing Necessary Components (cont d): 5. Effect Size: Smallest difference worth detecting (clinically)

9 What is a clinically important difference to detect? Standard drug has 75% Cure rate And New treatment... 76%?... 77%?... 78%?... 79%? 87%?... 88%?... 89%... 90%?

10 Cured rate for the New Treatment? Ridiculous notion... How would I know this I m doing the study to estimate the effect. I have no data on which to base an estimate True, but You do not estimate the cure rate for the new treatment! You determine the cure rate reflecting the clinically important difference to detect, which may have no relation to the actual cure rate

11 Example Standard drug Cost of $30.00 for 28 days 2 oral doses per day Minimal side effects New treatment Cost of $ for 28 days A single oral dose per day Neutropenia, blurred vision, and proteinuria

12 What is a clinically important difference to detect? Standard drug has 75% Cure rate And New treatment... 76%?... 77%?... 78%?... 79%? 87%?... 88%?... 89%... 90%? We believe 15% represents a clinically important difference to detect If the difference is greater then changes will occur If the difference is smaller, groups are considered equivalent (status quo preserved)

13 Sample Size for Hypothesis Testing Necessary Components (cont d): 6. Variability expected in the population For means (σ1, σ2) For proportions (P1, P2)

14 Sample Size for Hypothesis Testing Example for proportions: 1. Summary measure: Proportion Cured 2. Statistical Hypotheses: H 0 : Proportion cured is the same with both the new treatment and the standard treatment H 1 : Proportion cured is higher with the new treatment than with the standard treatment One sided vs. two sided Alternative Hypothesis.

15 Sample Size for Hypothesis Testing (cont-d) 3. Significance Level: α = 5% 4. Power: 1-β = 90% (never lower than 80%) 5. Effect size: P 2 P 1 = 15% n = Variability: Estimate for P 1 = 75% Estimate for P 2 = 90% Recommendation: a) a) Define level for for P for for the the baseline group b) b) Use effect size to to obtain level of of P for for the the study group

16 Main Determinant of Study Size Recommendations when budget is not enough: 1. (Estimation) Lower desired precision. 2. (Hypothesis Testing) Lower desired power or increase minimum detectable effect size. 3. It is not recommended to change confidence levels, significance levels, or variance estimates. 4. If after all these changes, budget is still insufficient, one has to decide between: Not conducting the study until enough budget has been obtained, or go ahead with the study knowing that the results are likely to be inconclusive (pilot study or exploratory).

17 Adjustments to Sample Size Non-Response (and attrition): n 2 = n 1 /(1-NR) n 2 = final size, n 1 = effective size NR = Non-response (and attrition) rate

18 Other Considerations Data dependencies (e.g., Matching, Repeated Measures). Multivariate methods (e.g., control for confounding). Multiplicity issues (e.g., Multiple testing, endpoints, treatments, interim analyses). Other variables of interest (e.g., time to event). Other hypotheses (e.g., equivalence).

19 Software PASS ( nquery ( EPI-INFO ( EPIDAT (

20 What should be included in the protocol? Justification in terms of power or precision for the primary endpoint Method used to calculate the sample size should be consistent with the primary method for data analysis and appropriate for the study design Historical data to support the assumptions Justification in terms of feasibility

21 Questions?

22 Exercise: Case Scenarios Statistical Hypotheses Significance level and desired power Effect size discussion

Sample Size Planning, Calculation, and Justification

Sample Size Planning, Calculation, and Justification Sample Size Planning, Calculation, and Justification Theresa A Scott, MS Vanderbilt University Department of Biostatistics theresa.scott@vanderbilt.edu http://biostat.mc.vanderbilt.edu/theresascott Theresa

More information

Analysis Issues II. Mary Foulkes, PhD Johns Hopkins University

Analysis Issues II. Mary Foulkes, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011 TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued

More information

Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective

Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective Lilly Yue, Ph.D. Chief, Cardiovascular and Ophthalmic Devices Branch Division of Biostatistics CDRH/FDA

More information

Workshop on Impact Evaluation of Public Health Programs: Introduction. NIE-SAATHII-Berkeley

Workshop on Impact Evaluation of Public Health Programs: Introduction. NIE-SAATHII-Berkeley Workshop on Impact Evaluation of Public Health Programs: Introduction NHRM Goals & Interventions Increase health service use and healthrelated community mobilization (ASHAs) Increase institutional deliveries

More information

Statistics in Medicine Research Lecture Series CSMC Fall 2014

Statistics in Medicine Research Lecture Series CSMC Fall 2014 Catherine Bresee, MS Senior Biostatistician Biostatistics & Bioinformatics Research Institute Statistics in Medicine Research Lecture Series CSMC Fall 2014 Overview Review concept of statistical power

More information

Two-Sample T-Tests Assuming Equal Variance (Enter Means)

Two-Sample T-Tests Assuming Equal Variance (Enter Means) Chapter 4 Two-Sample T-Tests Assuming Equal Variance (Enter Means) Introduction This procedure provides sample size and power calculations for one- or two-sided two-sample t-tests when the variances of

More information

Study Design and Statistical Analysis

Study Design and Statistical Analysis Study Design and Statistical Analysis Anny H Xiang, PhD Department of Preventive Medicine University of Southern California Outline Designing Clinical Research Studies Statistical Data Analysis Designing

More information

Two-Sample T-Tests Allowing Unequal Variance (Enter Difference)

Two-Sample T-Tests Allowing Unequal Variance (Enter Difference) Chapter 45 Two-Sample T-Tests Allowing Unequal Variance (Enter Difference) Introduction This procedure provides sample size and power calculations for one- or two-sided two-sample t-tests when no assumption

More information

Fixed-Effect Versus Random-Effects Models

Fixed-Effect Versus Random-Effects Models CHAPTER 13 Fixed-Effect Versus Random-Effects Models Introduction Definition of a summary effect Estimating the summary effect Extreme effect size in a large study or a small study Confidence interval

More information

AIE: 85-86, 193, 217-218, 294, 339-340, 341-343, 412, 437-439, 531-533, 682, 686-687 SE: : 339, 434, 437-438, 48-454, 455-458, 680, 686

AIE: 85-86, 193, 217-218, 294, 339-340, 341-343, 412, 437-439, 531-533, 682, 686-687 SE: : 339, 434, 437-438, 48-454, 455-458, 680, 686 Knowledge and skills. (1) The student conducts laboratory investigations and fieldwork using safe, environmentally appropriate, and ethical practices. The student is expected to: (A) demonstrate safe practices

More information

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration

More information

How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible

How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible University of Florence Dept. of Neurosciences Careggi University Hospital Dept of Neurosciences How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible Luca Massacesi,

More information

How to get accurate sample size and power with nquery Advisor R

How to get accurate sample size and power with nquery Advisor R How to get accurate sample size and power with nquery Advisor R Brian Sullivan Statistical Solutions Ltd. ASA Meeting, Chicago, March 2007 Sample Size Two group t-test χ 2 -test Survival Analysis 2 2 Crossover

More information

IS 30 THE MAGIC NUMBER? ISSUES IN SAMPLE SIZE ESTIMATION

IS 30 THE MAGIC NUMBER? ISSUES IN SAMPLE SIZE ESTIMATION Current Topic IS 30 THE MAGIC NUMBER? ISSUES IN SAMPLE SIZE ESTIMATION Sitanshu Sekhar Kar 1, Archana Ramalingam 2 1Assistant Professor; 2 Post- graduate, Department of Preventive and Social Medicine,

More information

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06 CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health

More information

Mind on Statistics. Chapter 12

Mind on Statistics. Chapter 12 Mind on Statistics Chapter 12 Sections 12.1 Questions 1 to 6: For each statement, determine if the statement is a typical null hypothesis (H 0 ) or alternative hypothesis (H a ). 1. There is no difference

More information

Likelihood Approaches for Trial Designs in Early Phase Oncology

Likelihood Approaches for Trial Designs in Early Phase Oncology Likelihood Approaches for Trial Designs in Early Phase Oncology Clinical Trials Elizabeth Garrett-Mayer, PhD Cody Chiuzan, PhD Hollings Cancer Center Department of Public Health Sciences Medical University

More information

Morris Animal Foundation

Morris Animal Foundation General Information: Morris Animal Foundation First Award Proposal Morris Animal Foundation (MAF) is dedicated to funding proposals that are relevant to our mission of advancing the health and well-being

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Confidence Intervals for the Difference Between Two Means

Confidence Intervals for the Difference Between Two Means Chapter 47 Confidence Intervals for the Difference Between Two Means Introduction This procedure calculates the sample size necessary to achieve a specified distance from the difference in sample means

More information

Power Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power

Power Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power Power Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power By Jason C. Cole, PhD QualityMetric, Inc. Senior Consulting Scientist jcole@qualitymetric.com 310-539-2024 Consulting

More information

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies 26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation

More information

University of Maryland School of Medicine Master of Public Health Program. Evaluation of Public Health Competencies

University of Maryland School of Medicine Master of Public Health Program. Evaluation of Public Health Competencies Semester/Year of Graduation University of Maryland School of Medicine Master of Public Health Program Evaluation of Public Health Competencies Students graduating with an MPH degree, and planning to work

More information

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another

More information

Clinical trials for medical devices: FDA and the IDE process

Clinical trials for medical devices: FDA and the IDE process Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Summary and general discussion

Summary and general discussion Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we

More information

SAMPLING & INFERENTIAL STATISTICS. Sampling is necessary to make inferences about a population.

SAMPLING & INFERENTIAL STATISTICS. Sampling is necessary to make inferences about a population. SAMPLING & INFERENTIAL STATISTICS Sampling is necessary to make inferences about a population. SAMPLING The group that you observe or collect data from is the sample. The group that you make generalizations

More information

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of

More information

Biostatistics: Types of Data Analysis

Biostatistics: Types of Data Analysis Biostatistics: Types of Data Analysis Theresa A Scott, MS Vanderbilt University Department of Biostatistics theresa.scott@vanderbilt.edu http://biostat.mc.vanderbilt.edu/theresascott Theresa A Scott, MS

More information

Chapter 2. Hypothesis testing in one population

Chapter 2. Hypothesis testing in one population Chapter 2. Hypothesis testing in one population Contents Introduction, the null and alternative hypotheses Hypothesis testing process Type I and Type II errors, power Test statistic, level of significance

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

Methodology Understanding the HIV estimates

Methodology Understanding the HIV estimates UNAIDS July 2014 Methodology Understanding the HIV estimates Produced by the Strategic Information and Monitoring Division Notes on UNAIDS methodology Unless otherwise stated, findings in this report are

More information

Class 19: Two Way Tables, Conditional Distributions, Chi-Square (Text: Sections 2.5; 9.1)

Class 19: Two Way Tables, Conditional Distributions, Chi-Square (Text: Sections 2.5; 9.1) Spring 204 Class 9: Two Way Tables, Conditional Distributions, Chi-Square (Text: Sections 2.5; 9.) Big Picture: More than Two Samples In Chapter 7: We looked at quantitative variables and compared the

More information

KADI SARVA VISHWA VIDYALAYA GANDHINAGAR. Ph.D. Course Work SOCIAL WORK

KADI SARVA VISHWA VIDYALAYA GANDHINAGAR. Ph.D. Course Work SOCIAL WORK KADI SARVA VISHWA VIDYALAYA GANDHINAGAR Ph.D. Course Work In SOCIAL WORK Paper-I: Research Methodology Section-A (Common to all faculties) 1) Introduction to Research Methodology: Meaning of Research,

More information

Guidelines for AJO-DO submissions: Randomized Clinical Trials June 2015

Guidelines for AJO-DO submissions: Randomized Clinical Trials June 2015 Guidelines for AJO-DO submissions: Randomized Clinical Trials June 2015 Complete and transparent reporting allows for accurate assessment of the quality of trial and correct interpretation of the trial

More information

3.4 Statistical inference for 2 populations based on two samples

3.4 Statistical inference for 2 populations based on two samples 3.4 Statistical inference for 2 populations based on two samples Tests for a difference between two population means The first sample will be denoted as X 1, X 2,..., X m. The second sample will be denoted

More information

Use advanced techniques for summary and visualization of complex data for exploratory analysis and presentation.

Use advanced techniques for summary and visualization of complex data for exploratory analysis and presentation. MS Biostatistics MS Biostatistics Competencies Study Development: Work collaboratively with biomedical or public health researchers and PhD biostatisticians, as necessary, to provide biostatistical expertise

More information

Organizing Your Approach to a Data Analysis

Organizing Your Approach to a Data Analysis Biost/Stat 578 B: Data Analysis Emerson, September 29, 2003 Handout #1 Organizing Your Approach to a Data Analysis The general theme should be to maximize thinking about the data analysis and to minimize

More information

2 Precision-based sample size calculations

2 Precision-based sample size calculations Statistics: An introduction to sample size calculations Rosie Cornish. 2006. 1 Introduction One crucial aspect of study design is deciding how big your sample should be. If you increase your sample size

More information

Non-inferiority studies: non-sense or sense?

Non-inferiority studies: non-sense or sense? Non-inferiority studies: non-sense or sense? Prof. Emmanuel Lesaffre Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands L-Biostat, K.U.Leuven, Leuven, Belgium 1 2 3 1. Review of study

More information

Tests for Two Proportions

Tests for Two Proportions Chapter 200 Tests for Two Proportions Introduction This module computes power and sample size for hypothesis tests of the difference, ratio, or odds ratio of two independent proportions. The test statistics

More information

Interim Analysis in Clinical Trials

Interim Analysis in Clinical Trials Interim Analysis in Clinical Trials Professor Bikas K Sinha [ ISI, KolkatA ] Courtesy : Dr Gajendra Viswakarma Visiting Scientist Indian Statistical Institute Tezpur Centre e-mail: sinhabikas@yahoo.com

More information

Sample Size Determination in Clinical Trials HRM-733 CLass Notes

Sample Size Determination in Clinical Trials HRM-733 CLass Notes Sample Size Determination in Clinical Trials HRM-733 CLass Notes Lehana Thabane, BSc, MSc, PhD Biostatistician Center for Evaluation of Medicines St. Joseph s Heathcare 105 Main Street East, Level P1 Hamilton

More information

Defining the Beginning: The Importance of Research Design

Defining the Beginning: The Importance of Research Design Research and Management Techniques for the Conservation of Sea Turtles K. L. Eckert, K. A. Bjorndal, F. A. Abreu-Grobois, M. Donnelly (Editors) IUCN/SSC Marine Turtle Specialist Group Publication No. 4,

More information

How To Check For Differences In The One Way Anova

How To Check For Differences In The One Way Anova MINITAB ASSISTANT WHITE PAPER This paper explains the research conducted by Minitab statisticians to develop the methods and data checks used in the Assistant in Minitab 17 Statistical Software. One-Way

More information

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age Background paper for SAGE discussions SAGE non-specific

More information

What does qualitative research have to offer evidence based health care? Brian Williams. Division of Community Health Sciences, University of Dundee

What does qualitative research have to offer evidence based health care? Brian Williams. Division of Community Health Sciences, University of Dundee What does qualitative research have to offer evidence based health care? Brian Williams Division of Community Health Sciences, University of Dundee Qualitative Methods Participant observation In depth

More information

Certified in Public Health (CPH) Exam CONTENT OUTLINE

Certified in Public Health (CPH) Exam CONTENT OUTLINE NATIONAL BOARD OF PUBLIC HEALTH EXAMINERS Certified in Public Health (CPH) Exam CONTENT OUTLINE April 2014 INTRODUCTION This document was prepared by the National Board of Public Health Examiners for the

More information

The PCORI Methodology Report. Appendix A: Methodology Standards

The PCORI Methodology Report. Appendix A: Methodology Standards The Appendix A: Methodology Standards November 2013 4 INTRODUCTION This page intentionally left blank. APPENDIX A A-1 APPENDIX A: PCORI METHODOLOGY STANDARDS Cross-Cutting Standards for PCOR 1: Standards

More information

Knowledge Objectives (2 of 2) Skills Objectives. Introduction. Process of Elimination (1 of 2) 12/20/2013

Knowledge Objectives (2 of 2) Skills Objectives. Introduction. Process of Elimination (1 of 2) 12/20/2013 Fire Cause Determination Knowledge Objectives (1 of 2) Discuss the use of the process of elimination when determining fire cause. Explain the roles source and form of heat of ignition play in fire cause.

More information

Fairfield Public Schools

Fairfield Public Schools Mathematics Fairfield Public Schools AP Statistics AP Statistics BOE Approved 04/08/2014 1 AP STATISTICS Critical Areas of Focus AP Statistics is a rigorous course that offers advanced students an opportunity

More information

Study Design Sample Size Calculation & Power Analysis. RCMAR/CHIME April 21, 2014 Honghu Liu, PhD Professor University of California Los Angeles

Study Design Sample Size Calculation & Power Analysis. RCMAR/CHIME April 21, 2014 Honghu Liu, PhD Professor University of California Los Angeles Study Design Sample Size Calculation & Power Analysis RCMAR/CHIME April 21, 2014 Honghu Liu, PhD Professor University of California Los Angeles Contents 1. Background 2. Common Designs 3. Examples 4. Computer

More information

Elements of statistics (MATH0487-1)

Elements of statistics (MATH0487-1) Elements of statistics (MATH0487-1) Prof. Dr. Dr. K. Van Steen University of Liège, Belgium December 10, 2012 Introduction to Statistics Basic Probability Revisited Sampling Exploratory Data Analysis -

More information

Guide to Biostatistics

Guide to Biostatistics MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading

More information

The Product Review Life Cycle A Brief Overview

The Product Review Life Cycle A Brief Overview Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review

More information

Snap shot. Cross-sectional surveys. FETP India

Snap shot. Cross-sectional surveys. FETP India Snap shot Cross-sectional surveys FETP India Competency to be gained from this lecture Design the concept of a cross-sectional survey Key areas The concept of a survey Planning a survey Analytical cross-sectional

More information

TAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors

TAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors TAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors Otis Johnson, Vice President, Clinical Research Susie Kim, Associate

More information

EORTC position on the place for transparency in the clinical trials regulation

EORTC position on the place for transparency in the clinical trials regulation EORTC position on the place for transparency in the clinical trials regulation EORTC fully supports the need to increase transparency of clinical trials. Appropriate transparency within the clinical trials

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 Current

More information

12: Analysis of Variance. Introduction

12: Analysis of Variance. Introduction 1: Analysis of Variance Introduction EDA Hypothesis Test Introduction In Chapter 8 and again in Chapter 11 we compared means from two independent groups. In this chapter we extend the procedure to consider

More information

Guidance for Industry

Guidance for Industry Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance

More information

The Application of Exploratory Data Analysis (EDA) in Auditing

The Application of Exploratory Data Analysis (EDA) in Auditing The Application of Exploratory Data Analysis (EDA) in Auditing Qi Liu Ph.D. Candidate (A.B.D.) Dept. of Accounting & Information Systems Rutgers University 28 th WCARS November 9, 2013 Outline Introduction

More information

Clinical Study Design and Methods Terminology

Clinical Study Design and Methods Terminology Home College of Veterinary Medicine Washington State University WSU Faculty &Staff Page Page 1 of 5 John Gay, DVM PhD DACVPM AAHP FDIU VCS Clinical Epidemiology & Evidence-Based Medicine Glossary: Clinical

More information

1. What is the critical value for this 95% confidence interval? CV = z.025 = invnorm(0.025) = 1.96

1. What is the critical value for this 95% confidence interval? CV = z.025 = invnorm(0.025) = 1.96 1 Final Review 2 Review 2.1 CI 1-propZint Scenario 1 A TV manufacturer claims in its warranty brochure that in the past not more than 10 percent of its TV sets needed any repair during the first two years

More information

Implications of dose rounding intravenous chemotherapy at a community based hospital

Implications of dose rounding intravenous chemotherapy at a community based hospital Implications of dose rounding intravenous chemotherapy at a community based hospital 1 2 ABSTRACT OBJECTIVES: To quantify and evaluate the total number of pharmacist interventions completed for dose rounding

More information

Performance Excellence Process

Performance Excellence Process Performance Excellence Process The Performance Excellence Process is a resultsoriented, long-term approach to the way government does business It uses several best practice methodologies, including Strategy

More information

Guidance for Industry

Guidance for Industry Guidance for Industry E9 Statistical Principles for Clinical Trials U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Department/Academic Unit: Public Health Sciences Degree Program: Biostatistics Collaborative Program

Department/Academic Unit: Public Health Sciences Degree Program: Biostatistics Collaborative Program Department/Academic Unit: Public Health Sciences Degree Program: Biostatistics Collaborative Program Department of Mathematics and Statistics Degree Level Expectations, Learning Outcomes, Indicators of

More information

Section 13, Part 1 ANOVA. Analysis Of Variance

Section 13, Part 1 ANOVA. Analysis Of Variance Section 13, Part 1 ANOVA Analysis Of Variance Course Overview So far in this course we ve covered: Descriptive statistics Summary statistics Tables and Graphs Probability Probability Rules Probability

More information

Statistics I for QBIC. Contents and Objectives. Chapters 1 7. Revised: August 2013

Statistics I for QBIC. Contents and Objectives. Chapters 1 7. Revised: August 2013 Statistics I for QBIC Text Book: Biostatistics, 10 th edition, by Daniel & Cross Contents and Objectives Chapters 1 7 Revised: August 2013 Chapter 1: Nature of Statistics (sections 1.1-1.6) Objectives

More information

1. FORMULATING A RESEARCH QUESTION

1. FORMULATING A RESEARCH QUESTION W R I T I N G A R E S E A R C H G R A N T P R O P O S A L 1. FORMULATING A RESEARCH QUESTION 1.1. Identify a broad area of interest through literature searches, discussions with colleagues, policy makers

More information

Planning sample size for randomized evaluations

Planning sample size for randomized evaluations TRANSLATING RESEARCH INTO ACTION Planning sample size for randomized evaluations Simone Schaner Dartmouth College povertyactionlab.org 1 Course Overview Why evaluate? What is evaluation? Outcomes, indicators

More information

Standard Deviation Estimator

Standard Deviation Estimator CSS.com Chapter 905 Standard Deviation Estimator Introduction Even though it is not of primary interest, an estimate of the standard deviation (SD) is needed when calculating the power or sample size of

More information

James E. Bartlett, II is Assistant Professor, Department of Business Education and Office Administration, Ball State University, Muncie, Indiana.

James E. Bartlett, II is Assistant Professor, Department of Business Education and Office Administration, Ball State University, Muncie, Indiana. Organizational Research: Determining Appropriate Sample Size in Survey Research James E. Bartlett, II Joe W. Kotrlik Chadwick C. Higgins The determination of sample size is a common task for many organizational

More information

Experimental Design. Power and Sample Size Determination. Proportions. Proportions. Confidence Interval for p. The Binomial Test

Experimental Design. Power and Sample Size Determination. Proportions. Proportions. Confidence Interval for p. The Binomial Test Experimental Design Power and Sample Size Determination Bret Hanlon and Bret Larget Department of Statistics University of Wisconsin Madison November 3 8, 2011 To this point in the semester, we have largely

More information

Measurement in ediscovery

Measurement in ediscovery Measurement in ediscovery A Technical White Paper Herbert Roitblat, Ph.D. CTO, Chief Scientist Measurement in ediscovery From an information-science perspective, ediscovery is about separating the responsive

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

Comment of Consumer Reports Regarding Draft Guidance for Industry: Arsenic In Apple Juice Action Level Docket No. FDA-2012-D-0322

Comment of Consumer Reports Regarding Draft Guidance for Industry: Arsenic In Apple Juice Action Level Docket No. FDA-2012-D-0322 November 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852. Comment of Consumer Reports Regarding Draft Guidance for Industry:

More information

Priority Program Translational Oncology Applicants' Guidelines

Priority Program Translational Oncology Applicants' Guidelines Stiftung Deutsche Krebshilfe Dr. h.c. Fritz Pleitgen Präsident Spendenkonto Kreissparkasse Köln IBAN DE65 3705 0299 0000 9191 91 BIC COKSDE33XXX Priority Program Translational Oncology Applicants' Guidelines

More information

Comparing Two Groups. Standard Error of ȳ 1 ȳ 2. Setting. Two Independent Samples

Comparing Two Groups. Standard Error of ȳ 1 ȳ 2. Setting. Two Independent Samples Comparing Two Groups Chapter 7 describes two ways to compare two populations on the basis of independent samples: a confidence interval for the difference in population means and a hypothesis test. The

More information

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose

More information

Non-Parametric Tests (I)

Non-Parametric Tests (I) Lecture 5: Non-Parametric Tests (I) KimHuat LIM lim@stats.ox.ac.uk http://www.stats.ox.ac.uk/~lim/teaching.html Slide 1 5.1 Outline (i) Overview of Distribution-Free Tests (ii) Median Test for Two Independent

More information

Data Analysis, Research Study Design and the IRB

Data Analysis, Research Study Design and the IRB Minding the p-values p and Quartiles: Data Analysis, Research Study Design and the IRB Don Allensworth-Davies, MSc Research Manager, Data Coordinating Center Boston University School of Public Health IRB

More information

Enterprise RIM: Building the Business Case. Steve Gens. Bethesda Maryland: February 25, 2014. Managing Partner Gens and Associates, Inc.

Enterprise RIM: Building the Business Case. Steve Gens. Bethesda Maryland: February 25, 2014. Managing Partner Gens and Associates, Inc. Enterprise RIM: Building the Business Case Bethesda Maryland: February 25, 2014 Steve Gens Managing Partner Gens and Associates, Inc. Disclaimer The views and opinions expressed in the following PowerPoint

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10

More information

CHAPTER 8 Planning and Budgeting

CHAPTER 8 Planning and Budgeting Copyright 2008 by the Foundation of the American College of Healthcare Executives 6/8/07 Version 8-1 CHAPTER 8 Planning and Budgeting The planning process Budget types Statistics budget Revenue budget

More information

Pharmacy Service Initiation: Steps for New Clinical Pharmacy Leaders. Professional Practice Advisory Group

Pharmacy Service Initiation: Steps for New Clinical Pharmacy Leaders. Professional Practice Advisory Group Pharmacy Service Initiation: Steps for New Clinical Pharmacy Leaders Professional Practice Advisory Group 1 Objectives Define clinical leadership Identify qualities of clinical pharmacy leaders List challenges

More information

The Cox Proportional Hazards Model

The Cox Proportional Hazards Model The Cox Proportional Hazards Model Mario Chen, PhD Advanced Biostatistics and RCT Workshop Office of AIDS Research, NIH ICSSC, FHI Goa, India, September 2009 1 The Model h i (t)=h 0 (t)exp(z i ), Z i =

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.

More information

Estimation following a phase II/III clinical trial

Estimation following a phase II/III clinical trial Estimation following a phase II/III clinical trial Sue Todd Department of Mathematics and Statistics University of Reading joint work with Peter Kimani and Nigel Stallard Warwick Medical School Cambridge

More information

Confidence Intervals for One Standard Deviation Using Standard Deviation

Confidence Intervals for One Standard Deviation Using Standard Deviation Chapter 640 Confidence Intervals for One Standard Deviation Using Standard Deviation Introduction This routine calculates the sample size necessary to achieve a specified interval width or distance from

More information

Mary B Codd. MD, MPH, PhD, FFPHMI UCD School of Public Health, Physiotherapy & Pop. Sciences

Mary B Codd. MD, MPH, PhD, FFPHMI UCD School of Public Health, Physiotherapy & Pop. Sciences HRB / CSTAR Grant Applications Training Day Convention Centre Dublin, 9 th September 2010 Key Elements of a Research Protocol Mary B Codd. MD, MPH, PhD, FFPHMI UCD School of Public Health, Physiotherapy

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project.

Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project. MPH Epidemiology Following are detailed competencies which are addressed to various extents in coursework, field training and the integrative project. Biostatistics Describe the roles biostatistics serves

More information

Chapter 1: The Nature of Probability and Statistics

Chapter 1: The Nature of Probability and Statistics Chapter 1: The Nature of Probability and Statistics Learning Objectives Upon successful completion of Chapter 1, you will have applicable knowledge of the following concepts: Statistics: An Overview and

More information